New immunotherapy combo aims to treat leukemia without chemo
NCT ID NCT06985485
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a sequence of two immunotherapy drugs, blinatumomab and inotuzumab ozogamicin, in people with B-cell acute lymphoblastic leukemia (B-ALL). It includes newly diagnosed patients who are older or too frail for intensive chemotherapy, as well as those whose cancer has returned or still shows signs of disease after treatment. The goal is to see if this drug combination can improve survival and reduce the chance of relapse, while avoiding traditional chemotherapy side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab and inotuzumab ozogamicin
- What this could lead to
- If successful, this could offer a chemotherapy-free immunotherapy option for B-ALL patients who cannot tolerate or decline intensive chemo, potentially improving survival and reducing relapse.
- What could go wrong
- This is a small, early-phase (phase II) single-center trial with only 26 participants, so results may not apply broadly. The combination may cause serious side effects like cytokine release syndrome or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- Can donor immune cells be engineered to fight blood cancer?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests